Optimized medical BPH treatment — Competitive Intelligence Brief

Optimized medical BPH treatment (Optimized medical BPH treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic receptor antagonist. Area: Urology.

phase 3 Alpha-1 adrenergic receptor antagonist Alpha-1 adrenergic receptor Urology Small molecule

Target snapshot

Optimized medical BPH treatment (Optimized medical BPH treatment) — University Hospital, Bordeaux. This drug targets the alpha-1 adrenergic receptor to relax smooth muscle in the prostate.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Optimized medical BPH treatment TARGET	Optimized medical BPH treatment	University Hospital, Bordeaux	phase 3	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
Articaine Hydrochloride + Epinephrine	Articaine Hydrochloride + Epinephrine	Ankara Yildirim Beyazıt University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
Buffered Articaine Hydrochloride + Epinephrine	Buffered Articaine Hydrochloride + Epinephrine	Ohio State University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
Metoprolol succinate + doxazosin	Metoprolol succinate + doxazosin	University of Colorado, Denver	marketed	Beta-blocker + Alpha-1 adrenergic antagonist combination	Beta-1 adrenergic receptor; Alpha-1 adrenergic receptor
Norepinephrine (static group)	Norepinephrine (static group)	Algemeen Ziekenhuis Maria Middelares	marketed	Catecholamine vasopressor	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor
Entecavir+Carvedilol	Entecavir+Carvedilol	ShuGuang Hospital	marketed	Antiviral + Beta-blocker combination	HBV reverse transcriptase; beta-1, beta-2, and alpha-1 adrenergic receptors
alpha blocker monotherapy	alpha blocker monotherapy	Samsung Medical Center	marketed	Alpha blocker	alpha-1 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic receptor antagonist class)

1. Brian J Lipworth · 1 drug in this class
2. CHU de Quebec-Universite Laval · 1 drug in this class
3. Eli Lilly and Company · 1 drug in this class
4. Haffkine Bio-Pharmaceutical Corporation Ltd. · 1 drug in this class
5. Hospital Authority, Hong Kong · 1 drug in this class
6. Japan Heart Foundation · 1 drug in this class
7. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
8. San Francisco Veterans Affairs Medical Center · 1 drug in this class
9. Sanofi · 1 drug in this class
10. Shanghai Huilun Pharmaceutical Co., Ltd. · 1 drug in this class